Hacettepe Üniversitesi Hastanelerin'de Takip Edilen Melanom Hastalarının Klinik Özellikleri, Uygulanan Tedavi Modaliteleri ve Sağ Kalımlarının Incelenmesi
Abstract
Melanoma is a rare type of cancer. There is not enough data about the melanoma
patients in our country. Therefore, we wanted to evaluate the clinical, pathological and
demographic data of the melanoma patients who were diagnosed and followed-up at
Hacettepe University Hospital which was one of the major cancer centers in Turkey.
According to the data from Hacettepe University Hospital Cancer Registry Unit, there
were 338 adult melanoma patients between January 2005-December 2013; and data was
retrospectively analyzed.
Of patients 57% was male and 43% was female. The mean age of patients was
55.2±15.2. The mean age was similar in both gender (p=0.652). The median age was
similar in both gender (p=0.652), while it was statistically significantly different
according to the melanoma subtypes (p=0.001). Skin melanoma, mucosal melanoma and
ocular melanoma was found in 169 (50%), 18 (5.3%) and 145 (42.9%) patients,
respectively. Primary origin of the melanoma was not found in 6 patients (1.8%).
When skin melanoma lesions analyzed in terms of localization, extremity origin was the
most common type (46.2%). The most common histologic type of skin melanoma was
superficial (34.3%). Among the patients with skin melanoma, best survival was
observed in lentigo malignant melanoma (average 86.1 months). Pathological subtype
was found to be a prognostic factor for survival in melanoma patients originated from
the skin (p<0.001). Accurate and reliable staging can be made in 82.8% of the cases.
Stage 2 was the most common (39.3%) and the least one was stage 4 patients. Stage was
a prognostic factor in terms of survival in melanoma patients originated from the skin
(p<0.001). The most common surgical treatment modality applied to 145 ocular
melanoma patients was enucleation. Forty-two patients (29%) were treated with one of
v
the radiotherapy methods. Adjuvant IFN was used in 35.5% of the patients. In 102
metastatic patients treated with chemotherapy, the most commonly used protocol was
temozolamide (78 patients, 75.7%). Among all the cases ipilimumab and vemurafenib
was applied to 17 and 16 patients, respectively.
This study is one of the most comprehensive studies examining all subtypes of
melanoma in Turkey.